FDA explains why it rejected Vanda’s stomach drug in late 2024news2025-01-15T18:21:45+00:00January 15th, 2025|Endpoints News|
HHS inspector general raises concerns over three FDA accelerated approvalsnews2025-01-14T20:32:47+00:00January 14th, 2025|Endpoints News|
BIO CEO plans to join FDA modernization advisory board under Trump administrationnews2025-01-13T21:22:29+00:00January 13th, 2025|Endpoints News|
FDA adcomm votes to support Seikagaku’s herniated disc injectionnews2025-01-10T21:24:46+00:00January 10th, 2025|Endpoints News|
Pfizer touts bladder cancer results as first advancement for some patients ‘in decades’news2025-01-10T19:17:13+00:00January 10th, 2025|Endpoints News|
Updated: CDER Director Patrizia Cavazzoni to step downnews2025-01-10T14:39:51+00:00January 10th, 2025|Endpoints News|
Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatmentnews2025-01-09T19:58:36+00:00January 9th, 2025|Endpoints News|
Catalyst staves off Firdapse competition from Teva for a decadenews2025-01-09T19:32:09+00:00January 9th, 2025|Endpoints News|
Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labelsnews2025-01-08T18:46:16+00:00January 8th, 2025|Endpoints News|
Ahead of adcomm, FDA discusses Seikagaku’s mixed trial results for its lumbar disc herniation injectionnews2025-01-08T18:40:01+00:00January 8th, 2025|Endpoints News|
